Login / Signup

Role of blood mSEPT9 in evaluating tumor burden and disease monitoring in colorectal cancer patients.

Huiqin JiangQian YuXinning ChenChunyan ZhangJunfei ShenMinna ShenYihui YangBei-Li WangBaishen PanWei Guo
Published in: Journal of clinical laboratory analysis (2021)
mSEPT9 was a biomarker reflecting tumor burden, and serial detections of mSEPT9 could be a promising strategy for disease monitoring in CRC patients.
Keyphrases
  • end stage renal disease
  • newly diagnosed
  • ejection fraction
  • chronic kidney disease
  • peritoneal dialysis
  • prognostic factors
  • risk factors
  • patient reported outcomes